Use of AI in Genetic Diagnosis: Identifying Rare Diseases

By HEOR Staff Writer

May 17, 2024

Introduction

Every year, numerous children are born with severe genetic disorders, with a considerable number remaining undiagnosed due to the complexity of identifying causative genetic variants. The emergence of artificial intelligence (AI) in genetic diagnosis offers a promising avenue for addressing these challenges, pushing the boundaries of precision medicine.

Understanding the Diagnostic Challenge

Genetic disorders, often resulting from single-gene mutations, present a significant diagnostic challenge. Despite modern bioinformatics tools, the process of pinpointing the exact variant responsible for a disease remains a complex task, demanding both time and extensive knowledge. Despite the advent of sophisticated bioinformatics tools, the diagnostic rate for genetic disorders hovers between 30 and 40%.  This complexity underscores the need for more efficient diagnostic methodologies.

Figure 1. Schematic Diagram Illustrating the Reanalysis Process

The Power of AI in Genetic Analysis

AI systems, such as AI-MARRVEL (AIM), have been developed to enhance the diagnostic process for Mendelian disorders. These systems leverage patient clinical features and sequencing profiles, offering a sophisticated approach to variant prioritisation. AIM, in particular, is trained on a more than 3.5 million variant data points and curated by certified experts, embodying a significant leap forward in genetic diagnostics.

Navigating the Limitations of Current Tools

While AI systems like AIM mark a significant advancement, they are not without limitations. The inability to analyse certain types of genetic variations and a focus on coding variants restrict their scope. However, these challenges present opportunities for further innovation and integration of more comprehensive analytical tools.

The Future of Genetic Diagnosis

AI in genetic diagnosis is not just a theoretical concept but a practical tool with a web interface for real-world application. It has the potential to truly enhance the periodic reanalysis of undiagnosed cases, making it a feasible and cost-effective option for many. As AI continues to evolve, its integration into clinical practice promises to enhance patient outcomes and set a new norm in genetic medicine.

Reference url

Recent Posts

Novartis Drug Discovery Innovation: Advancing Global Health Through Strategic R&D

By João L. Carapinha

February 26, 2026

Novartis drug discovery innovation is transforming global health through the Biomedical Research group's shift from siloed efforts to an integrated, patient-centric model targeting high-burden diseases in low- and middle-income countries (LMICs). Under Manju Ujjini, Head of Lead Discovery, key mi...
BIC LEN HIV Treatment: New Single-Tablet Regimen Shows Promising Results in ARTISTRY Trials
BIC/LEN HIV Treatment Maintains Suppression in Switch Studies Phase 3 results from Gilead Sciences' ARTISTRY-1 and ARTISTRY-2 trials, presented at the 2026 Conference on Retroviruses and Opportunistic Infections (CROI) an...
Novo Nordisk Announces Semaglutide Price Reduction to Improve Patient Access
Novo Nordisk Drives Semaglutide Price Reduction Novo Nordisk slashes the US semaglutide list price—or wholesale acquisition cost (WAC)—for Wegovy®, Ozempic®, and Rybelsus® to $675 per month across key doses, effective January 1, 2027....